We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Identifying microRNAs that can Serve as Biomarkers for Prostate Cancer

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Identifying microRNAs that can Serve as Biomarkers for Prostate Cancer"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Using Fluidigm Corporation's BioMark™ System and Digital Array™ integrated fluidic circuits (IFCs), researchers from the University of California San Francisco have identified serum microRNAs that can serve as biomarkers for prostate cancer.

To do this, the UCSF research group designed their own microRNA preAMP and PCR primers specifically to be used on the BioMark platform. Through this method, they were able to identify mRNA signatures that correlate with prognosis.

One in six men will be diagnosed with prostrate cancer during their lifetime. Recent prostate specific antigen (PSA) based screening trials indicate an urgent need for novel and non-invasive biomarker identification strategies to improve the prediction of prostate cancer behaviour. Non-coding microRNAs (miRNAs) in the serum and plasma have been shown to have potential as non-invasive markers for physiological and pathological conditions.

To identify serum miRNAs that diagnose and correlate with prognosis of prostate cancer, the researchers at UCSF developed a multiplex quantitative reverse transcription PCR (qRT-PCR) method involving purification of multiplex PCR products followed by uniplex analysis on a Fluidigm microfluidics chip to evaluate 384 human miRNAs.

Using Dgcr8 and Dicer knockout (small RNA - deficient) mouse ES cells (mESC) as the benchmark, the researchers confirmed the validity of their technique, while uncovering a significant lack of accuracy in previously published methods.

Profiling 48 sera from healthy men and untreated prostate cancer patients with differing CAPRA (Cancer of the Prostate Risk Assessment) scores, UCSF researchers identified miRNA signatures that allowed them to diagnose cancer patients and correlate with prognosis. These serum signatures included oncogenic and tumor suppressive miRNAs suggesting functional roles in prostate cancer progression.